医学
临床终点
内科学
肿瘤科
放化疗
临床研究阶段
腺癌
围手术期
化疗
新辅助治疗
胃肠病学
病态的
外科
临床试验
癌症
乳腺癌
作者
Jia Wei,Xiaofeng Lu,Qin Liu,Yao Shi Fu,Song Liu,Yang Zhao,Jiawei Zhou,Hui Chen,Meng Wang,Lin Li,Ju Yang,Fangcen Liu,Liming Zheng,Haitao Yin,Yang Yang,Chong Zhou,Ping Zeng,Xiaoyu Zhou,Naiqing Ding,Shiqing Chen
标识
DOI:10.1038/s41467-023-40480-x
摘要
Abstract In this multicenter, single-arm phase 2 trial (ChiCTR1900024428), patients with locally advanced gastric/gastroesophageal junction cancers receive one cycle of sintilimab (anti-PD1) and chemotherapy (S-1 and nab-paclitaxel), followed by 5 weeks of concurrent chemoradiotherapy and sintilimab, and another cycle of sintilimab and chemotherapy thereafter. Surgery is preferably scheduled within one to three weeks, and three cycles of adjuvant sintilimab and chemotherapy are administrated. The primary endpoint is the pathological complete response. Our results meet the pre-specified primary endpoint. Thirteen of 34 (38.2%) enrolled patients achieve pathological complete response (95% CI: 22.2-56.4). The secondary objectives include disease-free survival (DFS), major pathological response, R0 resection rate, overall survival (OS), event-free survival (EFS), and safety profile. The median DFS and EFS were 17.0 (95%CI: 11.1-20.9) and 21.1 (95%CI: 14.7-26.1) months, respectively, while the median OS was not reached, and the 1-year OS rate was 92.6% (95%CI: 50.1-99.5%). Seventeen patients (50.0%) have grade ≥3 adverse events during preoperative therapy. In prespecified exploratory biomarker analysis, CD3+ T cells, CD56+ NK cells, and the M1/M1 + M2-like macrophage infiltration at baseline are associated with pathological complete response. Here, we show the promising efficacy and manageable safety profile of sintilimab in combination with concurrent chemoradiotherapy for the perioperative treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI